___

• 1. Kumar SA, Sudhahar V, Varalakshmi P. Attenuation of serum lipid abnormalities and cardiac oxidative stress by eicosapentaenoate-lipoate (EPA-LA) derivative in experimental hypercholesterolemia. Clin Chim Acta 2005; 355: 197–204.
• 2. Hernandez-Trujillo Y, Rodriguez-Esparragon F, Macias-Reyes A, Caballero-Hidalgo A, Rodriguez-Perez JC. Rosiglitazone but not losartan prevents Nrf-2 dependent CD36 gene expression up-regulation in an in vivo atherosclerosis model. Cardiovasc Diabetol 2008; 7: 3.
• 3. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999; 99: 3092–3095.
• 4. Böger RH. Te emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res 2003; 59: 824–833.
• 5. Wakino S, Hayashi K, Tatematsu S, Hasegawa K, Takamatsu I, Kanda T, Homma K, Yoshioka K, Sugano N, Saruta T. Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats. Hypertens Res 2005; 28: 255–262.
• 6. Bełtowski J, Kedra A. Asymmetric dimethylarginine (ADMA) as a target for pharmacotherapy. Pharmacol Rep 2006; 58: 159– 178.
• 7. Bolayirli IM, Aslan M, Balci H, Altug T, Hacibekiroglu M, Seven A. Efects of atorvastatin therapy on hypercholesterolemic rabbits with respect to oxidative stress, nitric oxide pathway and homocysteine. Life Sci 2007; 81: 121–127.
• 8. Jayakumari N, Tejaseebai G. High prevalence of low serum paraoxonase-1 in subjects with coronary artery disease. J Clin Biochem Nutr 2009; 45: 278–284.
• 9. Yin QF, Xiong Y. Pravastatin restores DDAH activity and endothelium-dependent relaxation of rat aorta afer exposure to glycated protein. J Cardiovasc Pharmacol 2005; 45: 525–532.
• 10. Cortas NK, Wakid NW. Determination of inorganic nitrate in serum and urine by a kinetic cadmium-reduction method. Clin Chem 1990; 36: 1440–1443.
• 11. Jones CE, Darcy CJ, Woodberry T, Anstey NM, McNeil YR. HPLC analysis of asymmetric dimethylarginine, symmetric dimethylarginine, homoarginine and arginine in small plasma volumes using a gemine-NX column at high ph. Chromatogr B Analyt Technol Biomed Life Sci 2010; 878: 8–12.
• 12. Wu G, Meininger CJ. Analysis of citrulline, arginine, and methylarginines using high-performance liquid chromatography. Methods Enzymol 2008; 440: 177–189.
• 13. Durak I, Karabacak HI, Buyukkocak S, Cimen MY, Kacmaz M, Omeroglu E, Ozturk HS. Impaired antioxidant defense system in the kidney tissues from rabbits treated with cyclosporine. Protective efects of vitamins E and C. Nephron 1998; 78: 207– 211.
• 14. Navab M, Hama SY, Hough GP, Subbanagounder G, Reddy ST, Fogelman AM. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. Lipid Res 2001; 42: 1308–1317.
• 15. Daniil G, Phedonos AA, Holleboom AG, Motazacker MM, Argyri L, Kuivenhoven JA, Chroni A. Characterization of antioxidant/anti-infammatory properties and apo A-I- containing subpopulations of HDL from family subjects with monogenic low HDL disorders. Clin Chim Acta 2011; 412: 1213–1220.
• 16. Chen J, Costa LG, Guizzetti M. Assessment of cholesterol homeostasis in astrocytes and neurons. Methods Mol Biol 2011; 758: 403–414.
• 17. Taysi S, Demircan B, Akdeniz N, Atasoy M, Sari RA. Oxidant/ antioxidant status in men with Behçet’s disease. Clin Rheumatol 2007; 26: 418–422.
• 18. Sathyapalan T, Shepherd J, Coady AM, Kilpatrick ES, Atkin SL. Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. J Clin Endocrinol Meta 2012; 97: 3951–3955.
• 19. Ballantyne CM, Andrews TC, Hsia JA, Kramer JH, Shear C. ACCESS Study Group. Atorvastatin Comparative Cholesterol Efcacy and Safety Study. Correlation of non-high density lipoprotein cholesterol with apolipoprotein B: efect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on high-density lipoprotein levels. Am J Cardiol 2001; 88: 265– 269.
• 20. Andrikoula M, McDowell IF. The contribution of ApoB and ApoA1 measurements to cardiovascular risk assessment. Diabetes Obes Metab 2008; 10: 271–278.
• 21. Branchi A, Rovellini A, Fiorenza AM, Sommariva D. Effects of bezafbrate and of 2 HMG-CoA reductase inhibitors on lipoprotein (a) level in hypercholesterolemic patients. Int J Clin Pharmacol Ter 1995; 33: 345–350.
• 22. Bredie SJ, Westerveld HT, Knipscheer HC, de Bruin TW, Kastelein JJ, Stalenhoef AF. Efects of gemfbrozil or simvastatin on apolipoprotein-B-containing lipoproteins, apolipoprotein- CIII and lipoprotein (a) in familial combined hyperlipidaemia. Neth J Med 1996; 49: 59–67.
• 23. Goudevenos JA, Bairaktari ET, Chatzidimou KG, Milionis HJ, Mikhailidis DP, Elisaf MS. Te efect of atorvastatin on serum lipids, lipoprotein(a) and plasma fbrinogen levels in primary dyslipidaemia – a pilot study involving serial sampling. Curr Med Res Opin 2001; 16: 269–275.
• 24. Van Wissen S, Smilde TJ, Trip MD, de Boo T, Kastelein JJ, Stalenhoef AF. Long term statin treatment reduces lipoprotein (a) concentrations in heterozygous familial hypercholesterolaemia. Heart 2003; 89: 893–896.
• 25. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000; 101: 207–213.
• 26. Bolewski A, Lipiecki J, Plewa R, Burchardt P, Siminiak T. The efect of atorvastatin treatment on lipid profle and adhesion molecule levels in hypercholesterolemic patients: relation to low-density lipoprotein receptor gene polymorphism. Cardiology 2008; 111: 140–146.
• 27. Hong SC, Zhao SP, Wu ZH. Probucol up-regulates paraoxonase 1 expression in hepatocytes of hypercholesterolemic rabbits. J Cardiovasc Pharmacol 2006; 47: 77–81.
• 28. Harangi M, Seres I, Varga Z, Emri G, Szilvássy Z, Paragh G, Remenyik E. Atorvastatin efect on high-density lipoprotein- associated paraoxonase activity and oxidative DNA damage. Eur J Clin Pharmacol 2004; 60: 685–691.
• 29. Kural BV, Orem C, Uydu HA, Alver A, Orem A. Te efects of lipid-lowering therapy on paraoxonase activities and their relationships with the oxidant–antioxidant system in patients with dyslipidemia. Coron Artery Dis 2004; 15: 277–283.
• 30. Beltowski J, Wojcicka G, Mydlarczyk M, Jamroz A. Cerivastatin modulates plasma paraoxonase/arylesterase activity and oxidant-antioxidant balance in the rat. Pol J Pharmacol 2002; 54: 143–150.
• 31. Beltowski J, Wojcicka G, Jamroz A. Diferential efect of 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitors on plasma paraoxonase 1 activity in the rat. Pol J Pharmacol 2002; 54: 661–671.
• 32. Kassai A, Illyés L, Mirdamadi HZ, Seres I, Kalmár T, Audikovszky M, Paragh G. Te efect of atorvastatin therapy on lecithin: cholesterol acyltransferase, cholesteryl ester transfer protein and the antioxidant paraoxonase. Clin Biochem 2007; 40: 1–5.
• 33. Deakin SP, James RW. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin Sci (Lond) 2004; 107: 435–447.
• 34. Ansell BJ, Navab M, Watson KE, Fonarow GC, Fogelman AM. Anti-infammatory properties of HDL. Rev Endocr Metab Disord 2004; 5: 351–358.
• 35. Yano M, Matsumura T, Senokuchi T, Ishii N, Murata Y, Taketa K, Motoshima H, Taguchi T, Sonoda K, Kukidome D et al. Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages. Circ Res 2007; 100: 1442–1451.
• 36. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Tromb Vasc Biol 2001; 21: 473– 480.